|
Sep 4
|
WINREVAIR® (sotatercept) is now authorized for use in Canada for Adults with Pulmonary Arterial Hypertension
|
|
Sep 4
|
Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024
|
|
Sep 4
|
Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular Edema
|
|
Sep 4
|
EC approves Merck’s Keytruda-Padcev combo for urothelial cancer
|
|
Sep 4
|
Is Merck & Co., Inc. (MRK) the Best Cancer Stock to Buy Now?
|
|
Sep 3
|
Heard on the Street: Pfizer Better Watch Out for This Biotech
|
|
Sep 3
|
Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher
|
|
Sep 3
|
Vaxcyte’s “best-case” data for pneumococcal vaccine boost shares
|
|
Sep 3
|
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults
|
|
Aug 31
|
Merck & Co., Inc. (NYSE:MRK) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
|
|
Aug 30
|
Merck Scraps Two Late-Stage Keytruda Studies on Disappointing Data
|
|
Aug 29
|
Merck Pulls Plug On Two Keytruda Late-Stage Studies On Underwhelming Data
|
|
Aug 29
|
MSD discontinues two Phase III Keytruda trials
|
|
Aug 29
|
Keytruda fails lung and skin cancer trials, limiting further expansion
|
|
Aug 29
|
Merck to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
|
|
Aug 29
|
Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
|
|
Aug 28
|
MSD commences Phase III trial of thrombocythemia treatment
|
|
Aug 27
|
Do Options Traders Know Something About Merck (MRK) Stock We Don't?
|
|
Aug 27
|
RA Capital-backed startup raises $100M; UCB sells China business
|
|
Aug 27
|
Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential Thrombocythemia
|